Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
Record ID 32015000944
English
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie
Year Published:
2015
URL for published report:
http://eprints.hta.lbg.ac.at/1051/1/DSD_HSO_Nr.50.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Clinical Trials, Phase II as Topic
- Neoplasm Metastasis
- Nivolumab
- Antineoplastic Combined Chemotherapy Protocols
- Melanoma
- Skin Neoplasms
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.